Skip to menu Skip to content Skip to footer

A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoietin-resistant anaemia (ERA) in chronic kidney disease (2007-2012)

Abstract

That Oxpentifylline (Trental) administration will effectively treat erythropoietin or darbepoietin-resistant anaemia in chronic kidney disease patients.

Experts

Professor David Johnson

NHMRC Leadership Fellow
Frazer Institute
Faculty of Health, Medicine and Behavioural Sciences
David Johnson
David Johnson

Professor Carmel Hawley

Honorary Professor
Frazer Institute
Faculty of Health, Medicine and Behavioural Sciences
Carmel Hawley
Carmel Hawley